BNP/CALL/NOVO-NORDISK B/800/0.1/20.12.24 | Real-time Boerse Frankfurt Warrants 07:51:00 04/07/2024 pm IST | ||
| 2.79 EUR | -0.71% |
|
| Current month | -13.80% | ||
| 1 month | +18.07% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 2.79 | -0.71% |
| 03/24/03 | 2.81 | -2.09% |
| 02/24/02 | 2.87 | -8.31% |
| 01/24/01 | 3.13 | -3.99% |
| 28/24/28 | 3.26 | +2.52% |
Real-time Boerse Frankfurt Warrants
Last update July 04, 2024 at 07:51 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC367P |
| ISIN | DE000PC367P1 |
| Date issued | 30/01/2024 |
| Strike | 800 kr |
| Maturity | 20/12/2024 (169 Days) |
| Parity | 10 : 1 |
| Emission price | 0.76 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.43 € |
|---|---|
| Lowest since issue | 1.06 € |
| Spread | 0.04 € |
| Spread % | 1.41% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
